First-in-human Study to Examine Safety of a New Peritoneal Dialysis Device (WEAKID) in End-stage Kidney Disease Patients

NARecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 22, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Renal Insufficiency, ChronicKidney Failure, ChronicChronic Kidney Diseases
Interventions
DEVICE

WEAKID

"Six treatments over the course of two weeks with the WEAKID system:~* Week 1 (without the sorbents)~ * Day 1: four-hour treatment~ * Day 2: eight-hour treatment~ * Day 3: eight-hour treatment~* Week 2 (with the sorbents)~ * Day 1: four-hour treatment~ * Day 2: eight-hour treatment~ * Day 3: eight-hour treatment"

Trial Locations (3)

28029

NOT_YET_RECRUITING

Hospital Universario La Paz (SERMAS), Madrid

41121

NOT_YET_RECRUITING

Università degli studi di Modena e Reggio Emilia (UNIMORE), Modena

3584 CX

RECRUITING

University Medical Center Utrecht (UMCU), Utrecht

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Horizon 2020 - European Commission

OTHER

collaborator

Dutch Kidney Foundation

OTHER

collaborator

Health Holland

OTHER

collaborator

Nanodialysis Ltd

UNKNOWN

collaborator

Università degli studi di Modena e Reggio Emilia (UNIMORE)

UNKNOWN

collaborator

Servicio Madrileno De Salud (SERMAS)

UNKNOWN

collaborator

PPI Healthcare Consulting Ltd

UNKNOWN

lead

UMC Utrecht

OTHER

NCT06314503 - First-in-human Study to Examine Safety of a New Peritoneal Dialysis Device (WEAKID) in End-stage Kidney Disease Patients | Biotech Hunter | Biotech Hunter